Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a net loss compared to a prior net income, increased operating expenses, and a significant revenue decline due to the absence of last year's transaction. While there is a strong cash position and positive payer feedback, the financial performance is weak, with only modest sales of REDEMPLO. The Q&A indicates cautious optimism but lacks specific guidance, which could concern investors. Considering the market cap of $3.19 billion, these factors suggest a negative stock price movement in the next two weeks.
Key Financial Performance
Net Loss $132.7 million for the quarter ended March 31, 2026, compared to net income of $370.4 million in the prior year quarter. The change is primarily due to the absence of over $540 million in revenue from the Sarepta transaction recorded in the prior year.
Revenue $74 million for the quarter, driven by license and collaboration agreements with Sarepta and Novartis. This includes $42 million from Sarepta collaboration and $20 million from Novartis upfront payment.
Operating Expenses $215 million for the quarter, an increase of $53 million year-over-year. This was driven by $40 million higher R&D expenses and $13 million higher SG&A expenses, primarily due to ongoing Phase III studies and commercialization investments.
Cash and Investments Nearly $1.8 billion as of March 31, 2026, bolstered by over $1 billion raised during the quarter, including $850 million from financing transactions and $250 million from Sarepta payments.
REDEMPLO Net Sales Approximately $1 million for the quarter, representing the first full quarter of sales. This compares favorably to the first full commercial quarter of the other approved APOC3 inhibitor.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
REDEMPLO Launch: FDA approved REDEMPLO in November 2025 for reducing triglycerides in adults with FCS. The U.S. launch has been strong, with over 400 prescriptions written since launch, including 10% from competitor switches. Pricing is set at $45,000 per patient per year, reflecting its superior clinical profile. Internationally, REDEMPLO has received regulatory approvals in Australia, China, Canada, and a positive opinion in Europe. It will be marketed independently in Canada and Europe, and by Sanofi in China.
Pipeline Expansion: Arrowhead is advancing programs targeting genes in liver, skeletal muscle, adipose, CNS, and lung. Notable developments include the first dual functional siRNA targeting two genes and the CNS platform for Alzheimer's treatment. Clinical readouts for multiple programs are expected in 2026.
International Expansion of REDEMPLO: Regulatory approvals secured in Australia, China, Canada, and Europe. Marketing strategies include independent launches in Canada and Europe, and partnership with Sanofi in China.
Financial Strength: Arrowhead raised $1 billion through public offerings and achieved significant inflows from partnerships, resulting in a cash reserve of $1.8 billion as of March 2026. This ensures funding for ongoing clinical and commercial activities.
Commercial Infrastructure: Investments are being made to scale infrastructure for REDEMPLO's FCS launch and future SHTG opportunities. Geographic distribution of prescriptions is balanced across the U.S., indicating scalable patient identification capabilities.
Partnership with Madrigal Pharmaceuticals: Arrowhead licensed ARO-PNPLA3 to Madrigal for $25 million upfront, with potential milestone payments up to $975 million and royalties. This aligns with Arrowhead's strategy to partner on high-potential programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access and Pricing Challenges: The company faces challenges in payer coverage development and pricing strategy for REDEMPLO. While progress has been made, payer discussions are ongoing, and formulary coverage decisions are still pending. Additionally, the pricing strategy, including the reduction of REDEMPLO's list price to $45,000 per patient per year, reflects efforts to optimize market access but could impact revenue margins.
Regulatory and Approval Risks: The company is awaiting regulatory approvals in multiple regions, including the European Union and Canada, for REDEMPLO. Delays or negative outcomes in these approvals could hinder international expansion and revenue growth.
Clinical Trial and Development Risks: Several clinical trials, including SHASTA-3, SHASTA-4, and ARO-MAPT, are critical to the company's pipeline expansion. Any unfavorable data readouts or delays in these trials could impact the company's ability to file for regulatory approvals and commercialize new products.
Supply Chain and Operational Risks: The company is expanding its commercial infrastructure to support REDEMPLO and future products. However, scaling operations and ensuring consistent supply chain management could pose challenges, especially as the company enters new international markets.
Competitive Pressures: REDEMPLO faces competition from other APOC3 inhibitors. While the company claims a superior product profile, competitive pressures could impact market share and pricing power.
Economic and Financial Risks: The company reported a net loss of $132.7 million for the quarter, and while it has a strong balance sheet, ongoing R&D and commercialization expenses could strain financial resources if revenue growth does not meet expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
REDEMPLO Expansion: Arrowhead anticipates launching REDEMPLO in Canada, select EU countries, the U.K., and Greater China later this year, pending regulatory approvals. The company expects to market REDEMPLO independently in Canada and Europe, while Sanofi will handle marketing in Greater China.
SHASTA-3 and SHASTA-4 Studies: Top-line data from Phase III studies of plozasiran in severe hypertriglyceridemia (SHTG) patients are expected in Q3 2026. These results will support a supplemental NDA (sNDA) submission by the end of 2026, with potential regulatory approval in the second half of 2027.
ARO-DIMER-PA Clinical Data: Initial clinical data from the Phase I/II study of ARO-DIMER-PA, targeting mixed hyperlipidemia, is expected in Q3 2026. This program could lead to a unique therapy for approximately 20 million U.S. patients.
ARO-MAPT Clinical Data: Initial data from the Phase I/II study of ARO-MAPT, targeting tauopathies such as Alzheimer's disease, is anticipated by the end of Q3 or early Q4 2026. This program represents Arrowhead's first CNS platform candidate.
ARO-INHBE and ARO-ALK7 Updates: Additional data on ARO-INHBE and ARO-ALK7, targeting metabolic disorders and obesity, are expected in the second half of 2026. Arrowhead plans to launch a Phase II study for ARO-INHBE and provide further data on ARO-ALK7.
Zodasiran Development: The YOSEMITE Phase III study of zodasiran for homozygous familial hypercholesterolemia (HoFH) is on track for full enrollment in 2026, with potential NDA filings by the end of 2027.
Commercial Infrastructure Investments: Arrowhead is scaling its commercial infrastructure to support the current REDEMPLO launch for FCS and the anticipated SHTG opportunity, as well as future launches of other products.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the plan to pool SHASTA-3 and SHASTA-4 studies for pancreatitis analysis?
A:Yes, the plan is to pool SHASTA-3 and SHASTA-4 studies and analyze them using meta-analysis to look at pancreatitis event rates. The data is expected in Q3.
Q:What are the updates on INHBE and ALK 7 for obesity treatment?
A:The company believes INHBE and ALK 7 are interesting targets, particularly in combination with GLP-1s for type 2 diabetics. They have observed fat redistribution out of the liver and improvements in body composition. More data will be shared in the coming quarter and second half of the year.
Q:What feedback has been received from payers regarding the recent price lowering?
A:Interactions with payers have been positive, with payer policies reflecting the ability to diagnose FCS patients through multiple pathways. The price lowering was not due to payer pushback but to expand the market into SHTG and avoid step-through requirements with competitors.
Q:What are the motivations for patients switching to REDEMPLO?
A:The motivations for switching to REDEMPLO include efficacy, safety, tolerability, and other diverse reasons.
Q:Are the blinded AP event rates in SHASTA-3 and SHASTA-4 tracking as expected?
A:The company is not providing specific details but feels comfortable with the number of events observed. There are no plans to extend the study or remain blinded longer.
Q:How will Biogen's Phase III data impact the strategy for ARO-MAPT?
A:Positive data from Biogen's Phase III study would support the tau hypothesis and Alzheimer's programs. Even if the data is not positive, the company can still pursue other tauopathies like progressive supranuclear palsy or corticobasal dementia.
Q:What outcomes are expected from SHASTA-3 and SHASTA-4 studies to maintain premium pricing?
A:The company expects superior triglyceride reduction, safety profile, and convenience compared to competitors. The SHASTA-3 and SHASTA-4 studies use modified Atlanta criteria for pancreatitis events.
Q:What is the business development strategy for RNAi and other assets?
A:RNAi is seen as a leading genetic medicine modality. The company plans to push most of its pipeline forward independently, except for potential partnerships for C3 and Factor B. RNAi is preferred over gene editing for its reversibility and long durability.
Q:Is a construct combining INHBE or ALK 7 with another target being evaluated?
A:Yes, the company is evaluating constructs combining INHBE or ALK 7 with non-overlapping mechanism targets for obesity or other indications.
Q:Why is REDEMPLO priced at a premium compared to competitors?
A:REDEMPLO is considered best-in-class due to its superior APOC3 knockdown, triglyceride reduction, safety profile, and convenient dosing schedule of four injections per year.
Q:What are the expectations for ARO-DIMER readout later this year?
A:The focus will be on blood-based biomarkers like CSTK-09, APOC3, LDL cholesterol, and triglycerides. The company may conduct limited Phase II work before moving to an outcomes study.
Q:Why was the Madrigal license agreement for PNPLA pursued?
A:The company believes Madrigal is better positioned to develop and commercialize the drug due to its focus on NASH. The decision allows the company to allocate resources to its core pipeline.
Q:Review of Unclear Management Responses
A:The management avoided providing specific guidance on gross-to-net impact following the price lowering, stating a policy not to provide such guidance. Additionally, they did not disclose detailed event rates for SHASTA-3 and SHASTA-4 studies, only stating comfort with the observed numbers.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARO DIMER
Administration
Alzheimer disease
Arrowhead
China
DIMER PA
FCS launch
FCS patient
HTG
Head
III study
Novartis
Phase II
Phase III
Products
RD
SHASTA
TGs milligram
adult
awareness
capability
coverage
date
decision
dimer
dos
dynamic
expansion
infrastructure
label extension
momentum prescription
offering
plozasiran Phase
portfolio
prescription patient
prescription week
series
study plozasiran
tauopathies
transaction
volume
ARWR Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-10
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a net loss compared to a prior net income, increased operating expenses, and a significant revenue decline due to the absence of last year's transaction. While there is a strong cash position and positive payer feedback, the financial performance is weak, with only modest sales of REDEMPLO. The Q&A indicates cautious optimism but lacks specific guidance, which could concern investors. Considering the market cap of $3.19 billion, these factors suggest a negative stock price movement in the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Positive2-6
The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
ARWR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
